Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Free Cash Flow (Quarterly): -16.62M for Sept. 30, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -16.62M |
| June 30, 2023 | -15.18M |
| March 31, 2023 | -19.29M |
| December 31, 2022 | -18.42M |
| September 30, 2022 | -24.22M |
| June 30, 2022 | -21.66M |
| March 31, 2022 | -25.24M |
| December 31, 2021 | -16.89M |
| September 30, 2021 | -20.68M |
| June 30, 2021 | -66.57M |
| March 31, 2021 | -18.12M |
| December 31, 2020 | -15.22M |
| Date | Value |
|---|---|
| September 30, 2020 | -13.96M |
| June 30, 2020 | 37.40M |
| March 31, 2020 | -17.52M |
| December 31, 2019 | 33.35M |
| September 30, 2019 | -12.99M |
| June 30, 2019 | -14.27M |
| March 31, 2019 | -12.50M |
| December 31, 2018 | -6.601M |
| September 30, 2018 | -7.293M |
| June 30, 2018 | -6.662M |
| March 31, 2018 | -7.233M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-66.57M
Minimum
Jun 2021
37.40M
Maximum
Jun 2020
-14.78M
Average
-17.20M
Median
Free Cash Flow (Quarterly) Benchmarks
| Merck & Co Inc | 2.229B |
| Axonics Inc | -12.30M |
| Johnson & Johnson | 2.85B |
| Boston Scientific Corp | -81.00M |
| Ambrx Biopharma Inc (DELISTED) | -19.18M |